Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H17NO2 |
| Molecular Weight | 267.3224 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(O)C=C2[C@H]3[C@H](CCC2=C1)NCC4=CC=CC=C34
InChI
InChIKey=BGOQGUHWXBGXJW-YOEHRIQHSA-N
InChI=1S/C17H17NO2/c19-15-7-10-5-6-14-17(13(10)8-16(15)20)12-4-2-1-3-11(12)9-18-14/h1-4,7-8,14,17-20H,5-6,9H2/t14-,17-/m0/s1
| Molecular Formula | C17H17NO2 |
| Molecular Weight | 267.3224 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. Dihydrexidine was shown to stimulate cyclic AMP synthesis just as well or better than dopamine. It was the first dopamine D1 receptor agonist that had potent antiparkinsonian activity in a primate model of Parkinson's disease. Dihydrexidine produces hypothermia. Dihydrexidine has been shown to alleviate cognitive deficits or enhance cognitive performance in a number of animal models of cognition. It is under investigation for the improving the cognitive and working memory deficits in schizophrenia and schizotypal disorder.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues. | 2011-08-11 |
|
| Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. | 2005-10 |
|
| Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393. | 2004-02 |
|
| A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? | 2004 |
|
| Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. | 2002-09-15 |
|
| Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. | 2001-02 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 23:21:48 GMT 2025
by
admin
on
Tue Apr 01 23:21:48 GMT 2025
|
| Record UNII |
U4MPC92UC2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
757161-85-6
Created by
admin on Tue Apr 01 23:21:48 GMT 2025 , Edited by admin on Tue Apr 01 23:21:48 GMT 2025
|
PRIMARY | |||
|
U4MPC92UC2
Created by
admin on Tue Apr 01 23:21:48 GMT 2025 , Edited by admin on Tue Apr 01 23:21:48 GMT 2025
|
PRIMARY | |||
|
5311070
Created by
admin on Tue Apr 01 23:21:48 GMT 2025 , Edited by admin on Tue Apr 01 23:21:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
INNOVATOR->PARENT | |||
|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
|
RACEMATE -> ENANTIOMER |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
